论文部分内容阅读
目的观察奥卡西平(OXC)治疗癫疒间部分性发作/继发全面性强直-阵挛发作(PS/SGTCS)或特发性全面性强直-阵挛发作(GTCS)的疗效、耐受性和安全性。方法61例PS/SGTCS或GTCS患者,其中40例新诊断癫疒间和未经正规治疗的患者进入OXC单治组;而21例长期先后应用过多种抗癫疒间药治疗者进入OXC加治组。成人OXC起始量均为150 mg每晚1次,维持剂量(600~2 400)mg/d,分2次服用;儿童起始量(4~5)mg/kg每晚1次,维持剂量(30~40)mg/(kg.d)。进行自身对比开放性观察,同时分析单治组与加治组24周内的疗效、不良反应、耐受性和安全性。结果本组总有效率和显效率分别为62.3%和54.1%,控制率为49.2%,累积退出率为24.6%,3例(4.9%)失访,因不良反应和经济原因退出12例(19.7%),其中2例(3.3%)因皮疹退出。最常见的不良反应:乏力6例;头昏、头痛、嗜睡各5例;恶心、皮疹各2例。结论OXC治疗PS/SGTCS或GTCS的疗效明显,不良反应轻,耐受性好,安全性高。
Objective To observe the efficacy and tolerability of oxcarbazepine (OXC) in the treatment of partial epileptic seizures / secondary total tonic-clonic seizure (PS / SGTCS) or idiopathic tonic-clonic seizures (GTCS) And safety. Methods Sixty-one patients with PS / SGTCS or GTCS were enrolled in this study. Forty patients with newly diagnosed epilepsy and no formal treatment entered OXC group; 21 patients with long-term use of anti-epileptic drugs entered OXC plus treatment group group. The starting dose of OXC in adults was 150 mg once night, and the maintenance dose (600-2 400 mg / d) was given in 2 doses. The initial amount of children (4-5 mg / kg) (30-40) mg / (kg.d). To compare their openness and self-efficacy, and to analyze the curative effect, side effects, tolerability and safety within 24 weeks of single-and double-treatment groups. Results The total effective rate and markedly effective rate in this group were 62.3% and 54.1% respectively, the control rate was 49.2%, the cumulative withdrawal rate was 24.6% and 3 cases (4.9%) were lost to follow-up. Out of 12 patients due to adverse reactions and economic reasons (19.7 %), Of which 2 (3.3%) due to rash out. The most common adverse reactions: fatigue in 6 cases; dizziness, headache, lethargy in 5 cases; nausea, rash in 2 cases. Conclusion OXC treatment of PS / SGTCS or GTCS obvious effect, adverse reactions, tolerance, and high safety.